UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 98

Sortiert nach

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Clinical cancer research, 2005-08, Vol.11 (16), p.5878-5885

2005

Link zum Volltext

Verfügbarkeit prüfen

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.76 (3), p.354-361

2012

Link zum Volltext

Verfügbarkeit prüfen

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

Human molecular genetics, 2004-10, Vol.13 (20), p.2443-2449

2004

Link zum Volltext

Verfügbarkeit prüfen

Treatment and detection of ALK -rearranged NSCLC

Lung cancer (Amsterdam, Netherlands), 2013-08, Vol.81 (2), p.145-154

2013

Link zum Volltext

Verfügbarkeit prüfen

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

Cancer treatment reviews, 2014-09, Vol.40 (8), p.990-1004

2014

Link zum Volltext

Verfügbarkeit prüfen

Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma

Oncotarget, 2017-12, Vol.8 (63), p.106551-106564

2017

Link zum Volltext

Verfügbarkeit prüfen

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

Clinical cancer research, 2018-11, Vol.24 (21), p.5239-5249

2018

Link zum Volltext

Verfügbarkeit prüfen

MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer

Urologic oncology, 2020-07, Vol.38 (7), p.640.e23-640.e29

2020

Link zum Volltext

Verfügbarkeit prüfen

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2011-11, Vol.74 (2), p.326-331

2011

Link zum Volltext

Verfügbarkeit prüfen

Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer

Cancer control, 2003-07, Vol.10 (4), p.297-305

2003

Link zum Volltext

Verfügbarkeit prüfen

Molecular biology of castration resistant prostate cancer.

Archivos españoles de urología, 2018-09, Vol.71 (8), p.639-650

2018

Link zum Volltext

Verfügbarkeit prüfen

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

Future oncology (London, England), 2007-06, Vol.3 (3), p.277-283

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract 147: DNA methylation patterns are associated with cisplatin and docetaxel response and survival among NSCLC cases

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.147-147

2010

Link zum Volltext

Verfügbarkeit prüfen

IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors

Future oncology (London, England), 2009-04, Vol.5 (3), p.305-308

2009

Link zum Volltext

Verfügbarkeit prüfen

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2010-06, Vol.68 (3), p.491-497

2010

Link zum Volltext

Verfügbarkeit prüfen

Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan

Oncology reports, 2007-03, Vol.17 (3), p.637-645

2007

Link zum Volltext

Verfügbarkeit prüfen

Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop

Lung cancer (Amsterdam, Netherlands), 2011-12, Vol.74 (3), p.535-543

2011

Link zum Volltext

Verfügbarkeit prüfen

P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S527-S528

2007

Link zum Volltext

Verfügbarkeit prüfen

D5-02: Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemonaive non-small-cell lung cancer (NSCLC) patients (p)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S403-S403

2007

Link zum Volltext

Verfügbarkeit prüfen

D2-02: Excision repair cross complementing 6 (ERCC6) single nucleotide polymorphism (SNP) and outcome to gemcitabine(gem)/cisplatin(cis) or docetaxel(doc)/cis in stage IV non-small-cell lung cancer (NSCLC) patients (p)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S393-S393

2007

Link zum Volltext

Verfügbarkeit prüfen

P2-104: Role of ERCC1, XRCC3, Aurora A and TGFBR1 single nucleotide polymorphisms (SNP) and CHFR and 14-3-3 sigma methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer (NSCLC) patients (p)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S532-S533

2007

Link zum Volltext

Verfügbarkeit prüfen

P2-100: Real time RT-PCR based 3-gene expression signature predicts survival in early-stage squamous cell lung cancer (SqCLC)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S530-S531

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(95)

Publikationsform

Artikel
(98)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(52)
Science & Technology
(48)
Life Sciences & Biomedicine
(45)
Oncology
(42)
Lung Neoplasms - Drug Therapy
(31)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(30)
Carcinoma, Non-Small-Cell Lung - Genetics
(30)
Female
(30)
Male
(30)
Lung Neoplasms - Genetics
(29)
Middle Aged
(28)
Aged
(27)
Biological And Medical Sciences
(24)
Medical Sciences
(24)
Pneumology
(20)
Tumors Of The Respiratory System And Mediastinum
(20)
Adult
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)
Lung Cancer
(17)
Receptor, Epidermal Growth Factor - Genetics
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

CUL4A , ERCC5 , and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

Treatment and detection of ALK -rearranged NSCLC

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer

Molecular biology of castration resistant prostate cancer.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

Abstract 147: DNA methylation patterns are associated with cisplatin and docetaxel response and survival among NSCLC cases

IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan

Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop

P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations

D5-02: Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemonaive non-small-cell lung cancer (NSCLC) patients (p)

D2-02: Excision repair cross complementing 6 (ERCC6) single nucleotide polymorphism (SNP) and outcome to gemcitabine(gem)/cisplatin(cis) or docetaxel(doc)/cis in stage IV non-small-cell lung cancer (NSCLC) patients (p)

P2-104: Role of ERCC1, XRCC3, Aurora A and TGFBR1 single nucleotide polymorphisms (SNP) and CHFR and 14-3-3 sigma methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer (NSCLC) patients (p)

P2-100: Real time RT-PCR based 3-gene expression signature predicts survival in early-stage squamous cell lung cancer (SqCLC)

Suchergebnisse filtern